Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2011 | 12-2010 | 09-2010 | 06-2010 | 03-2010 | |
| Sales | 56,947 | 48,643 | 50,617 | 49,475 | 49,331 |
| Cost of Goods | 42,944 | 42,104 | 42,858 | 35,391 | 35,804 |
| Gross Profit | 14,003 | 6,539 | 7,759 | 14,084 | 13,527 |
| Operating Expenses | 16,038 | 57,532 | 23,883 | 20,440 | 14,206 |
| Operating Income | -1,091 | -50,889 | -15,266 | -5,965 | 125 |
| Interest Expense | 39 | 0 | 0 | 0 | 0 |
| Other Income | 39 | -397 | -597 | 192 | -45 |
| Pre-tax Income | -1,091 | -51,286 | -15,863 | -5,773 | 80 |
| Income Tax | 376 | -2,166 | -5,972 | -1,847 | 14 |
| Net Income Continuous | -1,467 | -49,120 | -9,891 | -3,926 | 66 |
| Net Income | $-1,467 | $-49,120 | $-9,891 | $-3,926 | $66 |
| EPS Basic Total Ops | -0.05 | -1.59 | -0.33 | -0.13 | 0.00 |
| EPS Basic Continuous Ops | -0.05 | -1.60 | -0.33 | -0.13 | 0.00 |
| EPS Diluted Total Ops | -0.05 | -1.59 | -0.33 | -0.13 | 0.00 |
| EPS Diluted Continuous Ops | -0.05 | -1.60 | -0.33 | -0.13 | 0.00 |
| EBITDA(a) | $3,306 | $-9,542 | $-10,601 | $-1,821 | $4,274 |